Earnings ·
Cytokinetics reports Q3 revenue of $47.6M as MYQORZO sales reach $44.5M
CYTKCytokinetics Inc
Cytokinetics reported third-quarter 2026 total revenues of $47.6 million, a significant increase from $1.9 million in the same period last year. Net product revenue for its drug MYQORZO (aficamten) reached $44.5 million, driven by growing prescriber adoption and international launches in the UK and Canada. The company reported a net loss of $190.1 million, or $(1.37) per share, compared to a net loss of $306.2 million, or $(2.55) per share, in the prior year period. Cytokinetics reaffirmed its full-year 2026 combined R&D and SG&A expense guidance of $860 million to $890 million. The company operates as a specialty cardiovascular biopharmaceutical firm developing treatments for cardiac muscle dysfunction.